Patents by Inventor Maria Mirotsou

Maria Mirotsou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Direct reprogramming of cells to cardiac myocyte fate
    Patent number: 11534464
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: December 27, 2022
    Assignee: Duke University
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • COMPOSITIONS AND METHODS OF TREATING VASCULAR DISEASES
    Publication number: 20220288131
    Abstract: The present invention generally relates to novel mesoderm-derived vascular progenitor cells (meso-VPCs) and methods of producing the meso-VPCs. The present invention also relates to methods of treating a vascular disease, such as critical limb ischemia, by administering the meso-VPCs into a subject.
    Type: Application
    Filed: August 27, 2020
    Publication date: September 15, 2022
    Inventors: Maria Mirotsou, Nutan Prasain, Amrita Singh, Robert Lanza
  • METHODS OF TREATING VASCULAR DISEASES
    Publication number: 20220280572
    Abstract: The present invention provides methods for treating vascular diseases with hemogenic endothelial cells (HEs) obtained in vitro from pluripotent stem cells. The present invention also provides compositions and methods of producing the HEs.
    Type: Application
    Filed: August 27, 2020
    Publication date: September 8, 2022
    Inventors: Nagisa Sakurai, Maria Mirotsou, Nutan Prasain, Amrita Singh, Robert Lanza
  • DIRECT REPROGRAMMING OF CELLS TO CARDIAC MYOCYTE FATE
    Publication number: 20200345786
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Application
    Filed: June 29, 2020
    Publication date: November 5, 2020
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • Direct reprogramming of cells to cardiac myocyte fate
    Patent number: 10695378
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: June 30, 2020
    Assignee: Duke University
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • INHIBITION OF HISTONE METHYLTRANSFERASE FOR CARDIAC REPROGRAMMING
    Publication number: 20190192533
    Abstract: A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression.
    Type: Application
    Filed: November 19, 2018
    Publication date: June 27, 2019
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Direct Reprogramming of Cells to Cardiac Myocyte Fate
    Publication number: 20180344776
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 6, 2018
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • Inhibition of histone methyltransferase for cardiac reprogramming
    Patent number: 10130637
    Abstract: A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: November 20, 2018
    Assignee: DUKE UNIVERSITY
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Direct reprogramming of cells to cardiac myocyte fate
    Patent number: 9987309
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: June 5, 2018
    Assignee: DUKE UNIVERSITY
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • STEM CELL DERIVED FACTORS FOR TREATING PATHOLOGIC CONDITIONS
    Publication number: 20170128526
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.
    Type: Application
    Filed: May 27, 2016
    Publication date: May 11, 2017
    Inventors: Victor Dzau, Maria Mirotsou
  • Method of reducing cell death by administering a paracrine factor derived from a mesenchymal stem cell
    Patent number: 9353168
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death and/or tissue injury associated with ischemic conditions.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: May 31, 2016
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DUKE UNIVERSITY
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Method of reducing cell death by administering a nucleic acid encoding a paracrine factor of a mesenchymal stem cell
    Patent number: 9279012
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: March 8, 2016
    Assignees: The Brigham and Women's Hospital, Inc., Duke University
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Inhibition of Histone Methyltransferase for Cardiac Reprogramming
    Publication number: 20150297611
    Abstract: A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression.
    Type: Application
    Filed: November 4, 2013
    Publication date: October 22, 2015
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Stem Cell Derived Factors for Treating Pathologic Conditions
    Publication number: 20140357703
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.
    Type: Application
    Filed: April 18, 2014
    Publication date: December 4, 2014
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Stem Cell Derived Factors for Treating Pathologic Conditions
    Publication number: 20140296152
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.
    Type: Application
    Filed: April 18, 2014
    Publication date: October 2, 2014
    Applicants: DUKE UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Method of reducing cell death by administering a paracrine factor of a mesenchymal stem cell
    Patent number: 8703710
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death and/or tissue injury associated with ischemic conditions.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: April 22, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Duke University
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Direct Reprogramming of Cells to Cardiac Myocyte Fate
    Publication number: 20140011281
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Application
    Filed: July 8, 2011
    Publication date: January 9, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • METHOD OF REDUCING CELL DEATH BY ADMINISTERING A PARACRINE FACTOR OF A MESENCHYMAL STEM CELL
    Publication number: 20120283183
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.
    Type: Application
    Filed: March 18, 2010
    Publication date: November 8, 2012
    Inventors: Victor Dzau, Maria Mirotsou
  • Use of HASF as a Protective Agent Against Ischemic Tissue Damage
    Publication number: 20120172306
    Abstract: A method of inducing a protective response against ischemic tissue damage is carried out by administering to subject a composition comprising an HASF polypeptide. The composition is administered prior to an ischemic event such as myocardial infarction to reduce tissue damage associated with such an event.
    Type: Application
    Filed: March 15, 2010
    Publication date: July 5, 2012
    Applicant: Duke University
    Inventors: Maria Mirotsou, Victor J. Dzau, Jing Huang
  • Method of reducing cell death by administering a Sfrp polypeptide
    Patent number: 8129344
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: March 6, 2012
    Assignees: Duke University, The Brigham and Women's Hospital, Inc.
    Inventors: Victor Dzau, Maria Mirotsou